



**Cadila Healthcare Limited**

Registered Office : Zydus Tower, Satellite Cross Roads, Ahmedabad - 380015.  
Tel. No. (+91-79) 2686 8100 Fax No. : (+91-79) 2686 2365/66 Website : www.zyduscadila.com

**Unaudited (Provisional) Financial Results for the Quarter ended September 30, 2010.**

CONSOLIDATED					Sr. No.	Particulars	COMPANY				
Rupees in Lacs [ except for share data ]							Rupees in Lacs [ except for share data ]				
3 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 3 Months Period ended on September 30, 2009 [Unaudited]	6 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2009 [Unaudited]	Previous accounting Year ended on March 31, 2010 [Audited]	3 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 3 Months Period ended on September 30, 2009 [Unaudited]	6 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2009 [Unaudited]	Previous accounting Year ended on March 31, 2010 [Audited]		
112,135	92,500	218,954	181,459	361,423	1	<b>Sales &amp; Income from operations :</b>	58,385	48,898	114,629	95,899	185,491
1,503	1,242	2,813	2,170	4,005	A	Gross Sales	882	747	1,703	1,221	2,198
110,632	91,258	216,141	179,289	357,418	B	Less : Excise Duty	57,503	48,151	112,926	94,678	183,293
1,037	3,320	8,906	5,643	11,267	C	Net Sales	16,400	16,245	39,314	29,292	59,196
111,669	94,578	225,047	184,932	368,685	D	Other Income from Operations	73,903	64,396	152,240	123,970	242,489
(1,959)	(1,654)	(3,651)	(4,273)	(11,334)	E	Total sales and other income from operations	(2,900)	2,279	(3,230)	2,020	(1,080)
29,786	22,845	56,250	44,910	97,889	2	<b>Expenditure :</b>	20,836	16,744	39,857	32,561	70,548
7,587	9,010	15,409	17,842	31,280	A	Increase [-] / Decrease [+] in stock in trade & work in progress	3,746	2,309	6,799	4,623	7,319
13,651	11,120	26,418	21,366	44,059	B	Consumption of materials	8,469	6,724	16,997	13,213	27,790
3,044	3,112	6,183	6,074	13,389	C	Purchase of traded goods	2,349	2,204	4,753	4,301	9,004
38,119	32,692	76,401	64,149	125,924	D	Employees cost	23,880	21,050	47,904	40,306	76,924
90,228	77,125	177,010	150,068	301,207	E	Depreciation, Amortisation & Impairment	56,380	51,310	113,080	97,024	190,505
21,441	17,453	48,037	34,864	67,478	F	Other Expenditure	17,523	13,086	39,160	26,946	51,984
385	411	672	833	1,591	G	Total Expenditure	2,368	1,110	3,942	2,374	4,351
21,826	17,864	48,709	35,697	69,069	3	<b>Profit from Operations before Other Income, Interest &amp; Exceptional Items [ 1 - 2 ]</b>	19,891	14,196	43,102	29,320	56,335
1,792	2,055	4,032	4,349	8,092	4	Other Income	923	968	2,168	2,322	4,263
(188)	253	727	394	122	5	<b>Profit before Interest &amp; Exceptional Items [ 3 + 4 ]</b>	(182)	158	10	322	45
1,604	2,308	4,759	4,743	8,214	6	Interest & financial charges	741	1,126	2,178	2,644	4,308
20,222	15,556	43,950	30,954	60,855	7	<b>Profit after Interest but before Exceptional Items [ 5 - 6 ]</b>	19,150	13,070	40,924	26,676	52,027
0	(258)	0	(350)	(464)	8	Exceptional Items [-] Income / [-] Expense	0	0	0	0	0
20,222	15,298	43,950	30,604	60,391	9	<b>Profit [+]/ Loss [-] from Ordinary Activities before tax [ 7 + 8 ]</b>	19,150	13,070	40,924	26,676	52,027
2,539	1,756	5,916	4,180	7,407	10	Tax expense	990	630	2,900	1,980	1,700
17,683	13,542	38,034	26,424	52,984	11	<b>Net Profit [+]/ Loss [-] from Ordinary Activities after tax [ 9 - 10 ]</b>	18,160	12,440	38,024	24,696	50,327
0	0	0	0	0	12	Extraordinary Items [ net of tax expense ]	0	0	0	0	0
17,683	13,542	38,034	26,424	52,984	13	<b>Net Profit [+]/ Loss [-] for the period [ 11 - 12 ]</b>	18,160	12,440	38,024	24,696	50,327
(599)	(350)	(1,032)	(753)	(2,470)	14	Adjustments on consolidation [+ ] Income / [- ] Expense	0	0	0	0	0
17,084	13,192	37,002	25,671	50,514	15	<b>Net Profit [+]/ Loss [-] for the period [ 13 + 14 ]</b>	18,160	12,440	38,024	24,696	50,327
10,237	6,824	10,237	6,824	6,824	16	Paid-up equity share capital [ Face Value Rs. 5/- ]	10,237	6,824	10,237	6,824	6,824
8.34	6.44 *	18.07	12.54 *	24.67 *	17	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	8.87	6.08 *	18.57	12.06 *	24.58 *
8.34	6.44 *	18.07	12.54 *	24.67 *	18	<b>Earnings Per Share [ EPS ] [ For the period - not Annualised ]:</b>	8.87	6.08 *	18.57	12.06 *	24.58 *
51,610,474	34,406,982	51,610,474	34,406,982	34,406,982	A	Basic and Diluted EPS before Extraordinary Items [ Rs. ]	8.87	6.08 *	18.57	12.06 *	24.58 *
25.21%	25.21%	25.21%	25.21%	25.21%	B	Basic and Diluted EPS after Extraordinary Items [ Rs. ]	8.87	6.08 *	18.57	12.06 *	24.58 *
Nil	Nil	Nil	Nil	Nil	19	<b>Public shareholding :</b>	51,610,474	34,406,982	51,610,474	34,406,982	34,406,982
N.A.	N.A.	N.A.	N.A.	N.A.		- Number of shares	25.21%	25.21%	25.21%	25.21%	25.21%
N.A.	N.A.	N.A.	N.A.	N.A.		- Percentage of Shareholding					
153,138,046	102,092,031	153,138,046	102,092,031	102,092,031	20	<b>Promoters and Promoter group Shareholding :</b>	153,138,046	102,092,031	153,138,046	102,092,031	102,092,031
100%	100%	100%	100%	100%	A	Pledged / Encumbered :	100%	100.00%	100%	100%	100.00%
74.79%	74.79%	74.79%	74.79%	74.79%		- Number of Shares	74.79%	74.79%	74.79%	74.79%	74.79%
						- Percentage of shares [ as a % of the total shareholding of promoters and promoter group ]					
					B	Non-encumbered :					
						- Number of Shares					
						- Percentage of shares [ as a % of the total shareholding of promoters and promoter group ]					
						- Percentage of shares [ as a % of the total share capital of the company ]					

**Notes :**

- The above results for the quarter ended on September 30, 2010 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on October 19, 2010.
- \* Earning per share in Item 18 A & B for the three / six months period ended on September 30, 2009 & previous accounting year ended on March 31, 2010 is calculated taking into account the allotment of bonus shares issued by the company, to make the figures comparable.
- The changes in Investments during the quarter are as under :  
Zydus BSV Pharma Pvt. Limited [ Additional Investment ] Rs. 110 Lacs  
Zydus Wellness Limited [ Additional Investment ] Rs. 55 Lacs
- During the quarter, the Company has formed two subsidiary companies in Mexico namely - (1) Zydus Pharmaceuticals Mexico S.A. de C.V. and (2) Zydus Pharmaceuticals Mexico Service Company.
- The status of investor complaints :  
Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 17, pending at the end of the quarter - Nil
- The Company has one segment of activity viz., "Pharmaceuticals".

Unaudited (Provisional) Statement of Assets & Liabilities as at September 30, 2010.									
CONSOLIDATED					Sr. No.	Particulars	COMPANY		
Rupees in Lacs							Rupees in Lacs		
6 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2009 [Unaudited]	Previous accounting Year ended on March 31, 2010 [Audited]	6 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2009 [Unaudited]	Previous accounting Year ended on March 31, 2010 [Audited]	6 Months Period ended on September 30, 2010 [Unaudited]	Corresponding 6 Months Period ended on September 30, 2009 [Unaudited]	Previous accounting Year ended on March 31, 2010 [Audited]	
10,237	6,824	6,824	10,237	6,824	6,824	10,237	6,824	6,824	
189,302	142,129	156,030	189,302	142,129	156,030	190,011	141,186	155,390	
109,023	122,211	109,054	109,023	122,211	109,054	60,257	77,376	59,413	
5,060	2,643	3,916	5,060	2,643	3,916	0	0	0	
11,457	13,188	11,407	11,457	13,188	11,407	11,804	12,594	11,494	
325,079	286,995	287,231	325,079	286,995	287,231	272,309	237,980	233,121	
204,736	180,776	193,262	204,736	180,776	193,262	114,391	103,140	109,329	
2,069	2,089	2,069	2,069	2,089	2,069	68,371	63,466	59,890	
83,744	69,852	75,040	83,744	69,852	75,040	45,058	34,644	38,083	
61,564	52,958	46,677	61,564	52,958	46,677	49,301	43,944	40,082	
26,346	33,094	25,072	26,346	33,094	25,072	3,054	4,217	2,822	
36,744	23,114	30,704	36,744	23,114	30,704	44,498	29,616	36,274	
83,084	68,405	67,100	83,084	68,405	67,100	47,796	36,977	38,308	
6,726	6,780	19,509	6,726	6,780	19,509	4,244	4,977	15,167	
(314)	297	1,016	(314)	297	1,016	(324)	887	116	
325,079	286,995	287,231	325,079	286,995	287,231	272,309	237,980	233,121	

For Cadila Healthcare Limited,

Pankaj R. Patel  
Chairman & Managing Director